• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 3, 2020

View Archived Issues
Cancer-and-Cancer-immunotherapy.png

Fate inks potential $3B immunotherapy deal with Janssen

Fate Therapeutics Inc. inked a multiyear, global collaboration worth up to $3 billion with Janssen Biotech Inc., which calls for the latter to contribute antigen binding domains for up to four tumor-associated targets. Read More
Symphogen-pic-4-3

Servier acquiring immuno-oncology partner Symphogen

DUBLIN – Les Laboratoires Servier SAS has thrown its partner Symphogen A/S a lifeline by agreeing to a takeover deal in which the Danish firm will become Servier’s center of excellence for antibody development. Read More
IPO money

Zentalis launches upsized IPO to warm reception despite market's larger losses

Against a backdrop of nearly 15 global biopharma IPOs on deck on a day when all major U.S. market indices fell, shares of cancer drug developer Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shot up 29% to $23.20 on April 3 after an upsized initial filing to sell 9.2 million shares at a top-of-range $18 each. Read More
Venbio-team-pic-4-3

Recessed entry: $394M funding door open in Venbio model despite hard times

Having chalked up three marketed drugs after only nine years in existence, Venbio Partners LLC proved its appeal yet again by closing on about $394 million in a capital raise that included new and existing investors, with a broad range of institutional concerns in the mix. Read More
newco-idea-hand-holding-lighbulb.png

Montis looking to exploit rather than inhibit tumor vasculature to target cancer

LONDON – A founding father of anti-angiogenesis therapy, Peter Carmeliet is turning his previous work on its head in new research which indicates that rather than destroying tumor vasculature, it should be piggy-backed as a means to recruit immune cells to a tumor. Read More
Colorectal cancer

Bench Press for April 3, 2020

BioWorld looks at translational medicine, including: Microbiome changes precede tumor development in CRC; Converting catch and release to PARP traps; Smart bacterium senses environment; The dose makes the poison – timing, too; Minimal phenotyping gives minimal insights into MDD genetics; Hypoxia linked to common form of muscular dystrophy; Stopping tau in its tracks; Optogenetic plaque model traces neurodegeneration in AD; Once repulsive, always repulsive. Read More

Appointments and advancements for April 3, 2020

New hires and promotions in the biopharma industry, including: Kaleido, Kodiak, Lumos. Read More

Financings for April 3, 2020

Biopharmas raising money in public or private financings, including: Oncology Venture, Phio, Vivus. Read More

In the clinic for April 3, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Axon, Denali, Neurocrine, Novan, Oryzon, Regeneron, Restorbio, Sanofi, Umecrine, Urogen, Voyager. Read More

Other news to note for April 3, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: American Cryostem, Aradigm, Brainstorm, Capricor, Celltrion, Emergent, Grifols, GSK, Icagen, Incyte, Innate, Innovax, Ligand, Neurocrine, Novartis, Regenerx, Ridgeback, Savara, Seneca, Siga, Sumitomo, Voltron. Read More

Regulatory actions for April 3, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cytodyn, Gracell, I-Mab, Iveric, Novan, Revive. Read More

Biopharma money raised: Jan. 1-April 2, 2020

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Money raised by biopharma: 2020 vs. 2019

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019. Read More

Biopharma money raised by quarter in 2020 (US$M)

Biopharma money raised to-date and by quarter in 2019, including public, private and other financings. Read More

Biggest gainers and losers for the week of March 30-April 3, 2020

The top 10 biopharma stock gainers and losers for the week. Read More

BioWorld and Nasdaq stock indices

These graphs compare the performance of the biotech stocks for all of 2020 using the BioWorld Stock Indicator and the Nasdaq Biotech Index. Read More
wall-street-stocks.png

Completed and pending biopharma IPOs in March 2020

Completed and pending initial public offerings by biopharma companies, including: Imara, Innocare Pharma. Read More

Follow-on offerings of biopharma companies in March 2020

Follow-ons completed by biopharma companies, including: Baudax, Cel-Sci, Compugen, Hoth, Kala, Seelos, Tiziana Life Sciences, Zogenix. Read More

Other financings of public biotechnology companies in March 2020

Private placements and other private financings of public biopharma companies, including: AB Science, Akari, Armata, Aytu, Baudax, Bellerophon, Biocurepharm, Brainstorm, Bridgebio, Cocrystal, Cytodyn, Emmaus Life Sciences, Enlivex, Equillium, Ethismos Research, Eton, Eyenovia, Helix, Hemostemix, IMV, Isofol Medical, Lattice, Marker, Moberg, Novan, Oncology Venture, Oncoquest, Pacylex, Plx, Predictive Oncology, Propanc, Protalix, Redx, Rockwell Medical, Theravance, Titan, Tonix, Unum, Vaccinex, Vaxart, Vaxil Bio, Verastem, Verrica, Vistagen, Xortx, Zosano. Read More

Venture capital and other private biopharma financings in March 2020

Venture capital and other private financings of private biopharma companies, including: Abbisko, Advanced Biodesign, Affinia, Akouos, AM-Pharma, Amunix, Apexigen, Biosight, Castle Creek, Cinclus, Circle, Clarus, Design, Elevatebio, Eureka, Evonetix, Exuma, Harbour Biomed, Immunocore, Kallyope, Keros, Kymera, Lipidio, Nanjing Iaso, Numab, Nurix, Oncoone R&D, Onethree, Pliant, Polyprox, Primmune, Recode, Redpin, Regenacy, Sigilon, Silverback, Sutrovax, Svenska Vaccinfabriken Produktion, Syndivia, Tikomed, Xilio, Zucara. Read More

Milestone payments from corporate partners in March 2020

Triggered milestone payments disclosed by biopharma companies, including: Abbvie, AC Immune, Boehringer Ingelheim, Cytomx, Eli Lilly, Oxford. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe